Literature DB >> 6968858

Fulminating noncardiogenic pulmonary edema. A newly recognized hazard during cardiac operations.

A T Culliford, S Thomas, F C Spencer.   

Abstract

At New York University Medical Center over the past 18 months, a distinctive and potentially lethal syndrome of fulminating noncardiogenic pulmonary edema has been observed in three patients following cardiopulmonary bypass. The clinical appearance is virtually identical to that produced by acute left ventricular failure, and the condition could have been diagnosed incorrectly in the past as myocardial infarction with left ventricular failure and pulmonary edema. Thus it is uncertain whether this is a new syndrome or whether it has long been present. Fulminating noncardiogenic pulmonary edema can be diagnosed by finding a low left atrial or pulmonary artery wedge pressure combined with a high protein content in the pulmonary edema fluid when compared to simultaneous measurements of the plasma protein level. As no other etiologic agent could be identified in our three patients, the probable cause seems to be an unknown type of allergic reaction to blood or blood products, manifested by acute pulmonary edema--the pulmonary capillary membranes being the first to be exposed to fluids administered intravenously. The significant point is that a nearly fatal degree of pulmonary congestion can be managed safely and effectively with corticosteroids, antihistamines, positive-pressure ventilation, diuretics, and albumin. Presently, two important questions remain: (1) Should fluids be restricted and balloon pump counterpulsation and vasopressors utilized to maintain systemic pressure? (2) How long after administration of steroids is it safe to give intravenous albumin? Meanwhile, both the mechanism and frequency of this syndrome remain unknown.

Entities:  

Mesh:

Year:  1980        PMID: 6968858

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  8 in total

Review 1.  Treatment of acute anaphylaxis.

Authors:  M Fisher
Journal:  BMJ       Date:  1995-09-16

2.  A comparison between 25% albumin and 6% hydroxyethyl starch solutions on lung water accumulation during and immediately after cardiopulmonary bypass.

Authors:  P D Lumb
Journal:  Ann Surg       Date:  1987-08       Impact factor: 12.969

3.  Sheep (Ovis aries) as a model for cardiovascular surgery and management before, during, and after cardiopulmonary bypass.

Authors:  Louis DiVincenti; Robin Westcott; Candice Lee
Journal:  J Am Assoc Lab Anim Sci       Date:  2014-09       Impact factor: 1.232

4.  Upper airway oedema following autologous blood transfusion from a wound drainage system.

Authors:  R Woda; J E Tetzlaff
Journal:  Can J Anaesth       Date:  1992-03       Impact factor: 5.063

5.  Neutrophils and their Fc gamma receptors are essential in a mouse model of transfusion-related acute lung injury.

Authors:  Mark R Looney; Xiao Su; Jessica A Van Ziffle; Clifford A Lowell; Michael A Matthay
Journal:  J Clin Invest       Date:  2006-05-18       Impact factor: 14.808

6.  T regulatory cells and dendritic cells protect against transfusion-related acute lung injury via IL-10.

Authors:  Rick Kapur; Michael Kim; Rukhsana Aslam; Mark J McVey; Arata Tabuchi; Alice Luo; Jonathan Liu; Yuan Li; Shanjeevan Shanmugabhavananthan; Edwin R Speck; Anne Zufferey; George Yousef; Haibo Zhang; Matthew T Rondina; Andrew S Weyrich; Leendert Porcelijn; Wolfgang M Kuebler; Arthur S Slutsky; John W Semple
Journal:  Blood       Date:  2017-02-15       Impact factor: 22.113

7.  Severe blood transfusion reaction from leukoagglutinin antibody with successful treatment by membrane oxygenation.

Authors:  A H Sabbagh; J M Fritz; M Riveros; R L Dexter
Journal:  Tex Heart Inst J       Date:  1982-03

8.  Delayed sternal closure as a safe adjunct to support biventricular failure after open heart surgery.

Authors:  R A Moggio; N Agarwal; R W Pooley; E D Somberg; P I Praeger; M R Sarabu; G E Reed
Journal:  Tex Heart Inst J       Date:  1986-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.